163 related articles for article (PubMed ID: 7905790)
1. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing.
Katsanis E; Bausero MA; Xu H; Orchard PJ; Xu Z; McIvor RS; Brian AA; Blazar BR
Cancer Immunol Immunother; 1994 Feb; 38(2):135-41. PubMed ID: 7905790
[TBL] [Abstract][Full Text] [Related]
2. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.
Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063
[TBL] [Abstract][Full Text] [Related]
3. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
[TBL] [Abstract][Full Text] [Related]
4. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
[TBL] [Abstract][Full Text] [Related]
5. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
6. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
7. Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins.
Akella R; Hall RE
Eur J Immunol; 1992 Apr; 22(4):1069-74. PubMed ID: 1348028
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors.
Katsanis E; Orchard PJ; Bausero MA; Gorden KB; McIvor RS; Blazar BR
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):81-90. PubMed ID: 8136949
[TBL] [Abstract][Full Text] [Related]
9. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
[TBL] [Abstract][Full Text] [Related]
10. Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.
Fady C; Gardner A; Gera JF; Lichtenstein A
Cancer Immunol Immunother; 1993 May; 36(5):307-14. PubMed ID: 8097427
[TBL] [Abstract][Full Text] [Related]
11. ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.
Chong AS; Jiang XL; Scuderi P; Lamas M; Graf LH
Cancer Immunol Immunother; 1994 Aug; 39(2):127-34. PubMed ID: 7519126
[TBL] [Abstract][Full Text] [Related]
12. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
13. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
14. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
[TBL] [Abstract][Full Text] [Related]
15. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis.
Goedegebuure PS; Braakman E; Segal DM; Vreugdenhil RJ; Bolhuis RL
Int Immunol; 1990; 2(12):1213-20. PubMed ID: 1982501
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
Fady C; Gardner A; Gera JF; Lichtenstein A
Cancer Immunol Immunother; 1993 Oct; 37(5):329-36. PubMed ID: 8104695
[TBL] [Abstract][Full Text] [Related]
18. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants.
Gross N; Favre S; Beck D; Meyer M
Int J Cancer; 1992 Aug; 52(1):85-91. PubMed ID: 1354203
[TBL] [Abstract][Full Text] [Related]
19. Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes.
Galocha B; López D; López de Castro JA
J Immunol; 1993 Mar; 150(5):1653-62. PubMed ID: 7679690
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
Foreman NK; Rill DR; Coustan-Smith E; Douglass EC; Brenner MK
Br J Cancer; 1993 May; 67(5):933-8. PubMed ID: 8494726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
